Idiopathic erythrocytosis (IE) is a primary erythrocytosis not fulfilling the criteria for polycythemia vera (PV) diagnosis. In order to verify the relationship between IE and PV, we screened JAK2V617F mutation in a consecutive series of 11 IE and, for comparison, in 15 PV. JAK2V617F mutation was screened by both cDNA sequencing and mutation specific PCR in both peripheral blood and bone marrow samples. All 11 IE tested negative for JAK2V617F mutation, which, conversely, occurred in 11/15 (73.3%) PV. Our results demonstrate that JAK2V617F is absent in IE and may represent a useful molecular marker for distinguishing IE from PV
It has been suggested that polycythemia vera (PV) could be preceded by an "early" phase of the disea...
The in vitro cultures of erythroid (BFU-E) and megakaryocytic (CFU-Meg) progenitors have been useful...
SummaryPolycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibr...
Idiopathic erythrocytosis (IE) is a primary erythrocytosis not fulfilling the criteria for polycythe...
Introduction: It is mandatory that every blood donor must have their haemoglobin (Hb) values measure...
The JAK2V617F point mutation has been described in 65 to 97% of patients with polycythemia vera (PV)...
Abstract Background Acquired erythrocytosis can be classified into polycythemia vera (PV) and non‐ne...
Subclones homozygous for JAK2V617F are more common in polycythemia vera (PV) than essential thromboc...
The diagnostic approach to a patient with polycythemia has been greatly simplified by the introducti...
BACKGROUND: An acquired V617F mutation in JAK2 occurs in most patients with polycythaemia vera, but ...
The diagnosis of polycythemia vera (PV) requires the integration of clinical and laboratory findings...
Although the pervasive presence of JAK2 in patients (pts) with PV has been noted in at least 7 publi...
We studied the relationship between JAK2 (V617F) mutant allele burden and clinical phenotype, diseas...
While about 95% of patients with polycythemia vera (PV) harbor the V617F mutation in JAK2 exon 14, s...
BACKGROUND: Myeloproliferative disorders are characterized by clonal expansion of normal mature bloo...
It has been suggested that polycythemia vera (PV) could be preceded by an "early" phase of the disea...
The in vitro cultures of erythroid (BFU-E) and megakaryocytic (CFU-Meg) progenitors have been useful...
SummaryPolycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibr...
Idiopathic erythrocytosis (IE) is a primary erythrocytosis not fulfilling the criteria for polycythe...
Introduction: It is mandatory that every blood donor must have their haemoglobin (Hb) values measure...
The JAK2V617F point mutation has been described in 65 to 97% of patients with polycythemia vera (PV)...
Abstract Background Acquired erythrocytosis can be classified into polycythemia vera (PV) and non‐ne...
Subclones homozygous for JAK2V617F are more common in polycythemia vera (PV) than essential thromboc...
The diagnostic approach to a patient with polycythemia has been greatly simplified by the introducti...
BACKGROUND: An acquired V617F mutation in JAK2 occurs in most patients with polycythaemia vera, but ...
The diagnosis of polycythemia vera (PV) requires the integration of clinical and laboratory findings...
Although the pervasive presence of JAK2 in patients (pts) with PV has been noted in at least 7 publi...
We studied the relationship between JAK2 (V617F) mutant allele burden and clinical phenotype, diseas...
While about 95% of patients with polycythemia vera (PV) harbor the V617F mutation in JAK2 exon 14, s...
BACKGROUND: Myeloproliferative disorders are characterized by clonal expansion of normal mature bloo...
It has been suggested that polycythemia vera (PV) could be preceded by an "early" phase of the disea...
The in vitro cultures of erythroid (BFU-E) and megakaryocytic (CFU-Meg) progenitors have been useful...
SummaryPolycythemia vera (PV), essential thrombocythemia (ET), and myeloid metaplasia with myelofibr...